Petros Pharmaceuticals Inc Stock

$0.04

4.79% yesterday

Nasdaq, Jun 27, 09:56 pm CET

ISIN

US71678J1007

Symbol

PTPI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Petros Pharmaceuticals Inc Stock price

$0.04

-1,437.46 100.00% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.00 5.99%

ISIN

US71678J1007

Symbol

PTPI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$1.1m

Enterprise Value

$4.6m

Net debt

$3.5m

Cash

$3.7m

Shares outstanding

420.0k

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.22 | 0.20

EV/Sales

0.91 | 0.83

EV/FCF

negative

P/B

0.00

Financial Health

Equity Ratio

-70.22%

Return on Equity

358.85%

ROCE

139.32%

ROIC

-231.89%

Debt/Equity

-0.97

Financials (TTM | estimate)

Revenue

$5.1m | $5.6m

EBITDA

$-7.5m | -

EBIT

$-10.3m

Net Income

$-26.8m | $-470.0k

Free Cash Flow

$-2.6m

Growth (TTM | estimate)

Revenue

-57.45% | 9.30%

EBITDA

54.57% | -

EBIT

53.61%

Net Income

-20.18% | 98.25%

Free Cash Flow

65.53%

Margin (TTM | estimate)

Gross

76.28%

EBITDA

-146.02% | -

EBIT

-201.40%

Net

-524.19% | -8.36%

Free Cash Flow

-51.40%

EPS

$-66.27

FCF per Share

$-6.26

Short interest

25.07%

Employees

21.00

Rev per Employee

$240.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Petros Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Petros Pharmaceuticals Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Petros Pharmaceuticals Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Petros Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	5.11 5.11	57% 57% 100%
- Direct Costs	1.21 1.21	61% 61% 24%
Gross Profit	3.90 3.90	56% 56% 76%
- Selling and Administrative Expenses	8.75 8.75	44% 44% 171%
- Research and Development Expense	2.62 2.62	34% 34% 51%
EBITDA	-7.46 -7.46	55% 55% -146%
- Depreciation and Amortization	2.83 2.83	51% 51% 55%
EBIT (Operating Income) EBIT	-10 -10	54% 54% -201%
Net Profit	-27 -27	20% 20% -524%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Petros Pharmaceuticals Inc Stock News

Neutral

Accesswire

●

3 days ago

Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position

NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals LLC ("Metuchen"), including its wholly owned subsidi...

Neutral

Accesswire

●

about one month ago

Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets

The Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces that it has received a staff determination letter from the Nasdaq Stock Market, LL...

Neutral

Accesswire

●

about one month ago

Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer

With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, toda...

More Petros Pharmaceuticals Inc News

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics. Its commercial capabilities include sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The firm operates through Prescription Medications and Medical Devices segments. The Prescription Medications segment consists primarily of Stendra, which is sold generally in the United States. The Medical Devices segment includes vacuum erection devices, which are sold domestically and internationally. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Head office	United States
CEO	John Shulman
Employees	21
Website	www.petrospharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now